NCT05798845 2026-03-11
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
Clinical Trials
34 trialsNCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT07413952 2026-02-17
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT07082179 2026-02-11
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT06738160 2026-02-06
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT07388771 2026-02-05
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
Tongji Hospital
Recruiting
NCT07379398 2026-01-30
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04557007 2026-01-29
Oncomabs
Oslo University Hospital
Terminated
NCT07358689 2026-01-22
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06576635 2026-01-20
LUNG-05
University of Illinois at Chicago
Phase NA Recruiting
NCT05089916 2026-01-14
ROSE
AIO-Studien-gGmbH
Phase 2 Active not recruiting
NCT07330037 2026-01-09
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04640259 2025-12-18
EoYLC
Addario Lung Cancer Medical Institute
Active not recruiting
NCT07281209 2025-12-15
A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT07247227 2025-11-25
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
Peking Union Medical College
Phase NA Recruiting
NCT07243899 2025-11-24
Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy
Shanghai Zhongshan Hospital
Completed
NCT07198217 2025-09-30
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
Zibo Municipal Hospital
Phase 2 Recruiting
NCT06448910 2025-09-24
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC
Fudan University
Phase 2 Active not recruiting
NCT07179445 2025-09-17
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting
NCT06865339 2025-09-10
TRIPL
Albert Einstein College of Medicine
Phase 2 Recruiting
NCT07156604 2025-09-05
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
Fudan University
Phase 2 Not yet recruiting
NCT07153770 2025-09-04
Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT05773092 2025-09-03
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT07134413 2025-08-21
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT05078931 2025-07-30
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT07089199 2025-07-28
TitAN
Qilu Hospital of Shandong University
Phase 2 Not yet recruiting
NCT06864624 2025-07-25
WU-KONG20
Tang-Du Hospital
Phase 2 Recruiting
NCT07085182 2025-07-25
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
Zibo Municipal Hospital
Phase 2 Recruiting
NCT07086326 2025-07-25
NEOINSPIRE
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT02284308 2025-07-04
ELDAPT
Maastricht Radiation Oncology
Active not recruiting
NCT06944470 2025-04-25
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Not yet recruiting
NCT00280189 2025-04-16
Study of Outcomes of Radiofrequency Ablation of Lung Tumors
University of Pittsburgh
Suspended
NCT06457789 2025-04-02
iRelate
Amsterdam UMC, location VUmc
Phase NA Recruiting
NCT06893354 2025-03-25
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
The First Affiliated Hospital of Guangzhou Medical University
Phase 4 Not yet recruiting